GlycoNex Business Summary

GlycoNex Inc. (4168.TWO) is a clinical-stage biotechnology firm specializing in the development of glycan-directed cancer immunotherapies and biosimilars. The company generates revenue through a hybrid model of proprietary drug licensing, milestone payments, and Contract Development and Manufacturing Organization (CDMO) services, supported by its 200L GMP-compliant antibody production facility. Its primary business segments are divided into new antibody drug development—centered on its lead humanized monoclonal antibody GNX102 and the GNX1021 antibody-drug conjugate (ADC)—and biosimilar programs, most notably the Phase 3 denosumab candidate SPD8. Within the Taiwanese biotech landscape, GlycoNex competes directly with OBI Pharma, Mycenax Biotech, and Golden Biotechnology, positioning itself as a specialized pioneer in targeting carbohydrate antigens to minimize off-target toxicity in solid tumor treatments. The company was founded in 2001 by Chairman Dr. Tong-Hsuan Chang, a former Director of Immunology at the Development Center for Biotechnology (DCB) and a Ph.D. graduate of the University of Tokyo, in collaboration with the late Dr. Sen-Itiroh Hakomori of The Biomembrane Institute. The current leadership is headed by President and CEO Dr. Mei-Chun Yang, who assumed the role in 2024 to oversee the transition of the ADC pipeline into global clinical trials. Technical and strategic operations are further supported by Dr. Wen-Han Lee (Strategy & Business Development) and Dr. Yen-Ying Chen (Clinical Development). Notable institutional backing and strategic partnerships include the Mitsubishi Gas Chemical Company (MGC) of Japan and recent co-development alliances with Nippon Kayaku to advance next-generation ADC candidates.